CN1186091C - 一种治疗肝病的注射液及其生产工艺 - Google Patents
一种治疗肝病的注射液及其生产工艺 Download PDFInfo
- Publication number
- CN1186091C CN1186091C CN 200310103393 CN200310103393A CN1186091C CN 1186091 C CN1186091 C CN 1186091C CN 200310103393 CN200310103393 CN 200310103393 CN 200310103393 A CN200310103393 A CN 200310103393A CN 1186091 C CN1186091 C CN 1186091C
- Authority
- CN
- China
- Prior art keywords
- extract
- amount
- water
- add
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002347 injection Methods 0.000 title claims abstract description 35
- 239000007924 injection Substances 0.000 title claims abstract description 35
- 239000003814 drug Substances 0.000 title claims abstract description 13
- 238000004519 manufacturing process Methods 0.000 title abstract description 6
- 241000222336 Ganoderma Species 0.000 claims abstract description 18
- 238000002360 preparation method Methods 0.000 claims abstract description 17
- 238000002156 mixing Methods 0.000 claims abstract description 13
- 208000019423 liver disease Diseases 0.000 claims abstract description 7
- 238000001914 filtration Methods 0.000 claims abstract description 5
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 66
- 239000000284 extract Substances 0.000 claims description 57
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 43
- 239000007788 liquid Substances 0.000 claims description 41
- 239000000706 filtrate Substances 0.000 claims description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 29
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 18
- 239000010231 banlangen Substances 0.000 claims description 18
- 239000008215 water for injection Substances 0.000 claims description 15
- 238000004321 preservation Methods 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 13
- 238000001556 precipitation Methods 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 11
- 229910021529 ammonia Inorganic materials 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 9
- 238000002386 leaching Methods 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 7
- 230000001105 regulatory effect Effects 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 238000009413 insulation Methods 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 238000004659 sterilization and disinfection Methods 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 4
- 230000027326 copulation Effects 0.000 claims description 4
- 238000005262 decarbonization Methods 0.000 claims description 4
- 230000014759 maintenance of location Effects 0.000 claims description 4
- 238000007670 refining Methods 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 11
- 102000004190 Enzymes Human genes 0.000 abstract description 3
- 108090000790 Enzymes Proteins 0.000 abstract description 3
- 238000000605 extraction Methods 0.000 abstract description 3
- 210000004185 liver Anatomy 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 206010023126 Jaundice Diseases 0.000 abstract description 2
- 230000001900 immune effect Effects 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract description 2
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 abstract 1
- 235000003097 Artemisia absinthium Nutrition 0.000 abstract 1
- 240000001851 Artemisia dracunculus Species 0.000 abstract 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 abstract 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 abstract 1
- 240000001972 Gardenia jasminoides Species 0.000 abstract 1
- 241000334160 Isatis Species 0.000 abstract 1
- 241000207929 Scutellaria Species 0.000 abstract 1
- 239000001138 artemisia absinthium Substances 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 238000005728 strengthening Methods 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000006837 decompression Effects 0.000 description 10
- 210000003494 hepatocyte Anatomy 0.000 description 7
- 238000004064 recycling Methods 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 229960004397 cyclophosphamide Drugs 0.000 description 5
- 239000012567 medical material Substances 0.000 description 5
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 206010067125 Liver injury Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 3
- 229960003321 baicalin Drugs 0.000 description 3
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229960001614 levamisole Drugs 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000008865 yin zhi huang Substances 0.000 description 3
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 2
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 2
- IBFYXTRXDNAPMM-BVTMAQQCSA-N Geniposide Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1C(=CC2)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBFYXTRXDNAPMM-BVTMAQQCSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 2
- 229940074393 chlorogenic acid Drugs 0.000 description 2
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 2
- 235000001368 chlorogenic acid Nutrition 0.000 description 2
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical compound S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000011265 semifinished product Substances 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 244000111489 Gardenia augusta Species 0.000 description 1
- 235000018958 Gardenia augusta Nutrition 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229940117953 phenylisothiocyanate Drugs 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200310103393 CN1186091C (zh) | 2002-11-01 | 2003-10-31 | 一种治疗肝病的注射液及其生产工艺 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02134005 CN1413730A (zh) | 2002-11-01 | 2002-11-01 | 舒肝注射液及其生产工艺 |
CN02134005.6 | 2002-11-01 | ||
CN 200310103393 CN1186091C (zh) | 2002-11-01 | 2003-10-31 | 一种治疗肝病的注射液及其生产工艺 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1486743A CN1486743A (zh) | 2004-04-07 |
CN1186091C true CN1186091C (zh) | 2005-01-26 |
Family
ID=34523588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200310103393 Expired - Lifetime CN1186091C (zh) | 2002-11-01 | 2003-10-31 | 一种治疗肝病的注射液及其生产工艺 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1186091C (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1813984B (zh) * | 2005-12-14 | 2011-08-31 | 贵州瑞和制药有限公司 | 治疗肝疾病的中药制剂及其制备方法 |
CN105395650B (zh) * | 2015-12-09 | 2019-08-16 | 贵州瑞和制药有限公司 | 舒肝宁制剂在制备治疗骨质疏松及其并发症药物中的应用 |
CN105412291B (zh) * | 2015-12-09 | 2019-08-20 | 贵州瑞和制药有限公司 | 舒肝宁在制备治疗糖尿病神经病变及并发症药物中的应用 |
CN105434342A (zh) * | 2015-12-21 | 2016-03-30 | 贵州瑞和制药有限公司龙里药厂 | 一种舒肝宁注射制剂的制备方法 |
CN105412294B (zh) * | 2015-12-21 | 2019-08-20 | 贵州瑞和制药有限公司 | 一种舒肝宁制剂的制作方法 |
CN105412295B (zh) * | 2015-12-21 | 2019-08-20 | 贵州瑞和制药有限公司 | 一种舒肝宁制剂的制作工艺 |
CN105902488A (zh) * | 2016-05-20 | 2016-08-31 | 贵州瑞和制药有限公司龙里药厂 | 一种舒肝宁制剂的制备工艺 |
CN105878469A (zh) * | 2016-05-20 | 2016-08-24 | 贵州瑞和制药有限公司龙里药厂 | 一种舒肝宁注射制剂的制作工艺 |
-
2003
- 2003-10-31 CN CN 200310103393 patent/CN1186091C/zh not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1486743A (zh) | 2004-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1154502C (zh) | 肾康注射液及其制备工艺 | |
CN1259935C (zh) | 一种治疗高脂血症的药物 | |
CN1186091C (zh) | 一种治疗肝病的注射液及其生产工艺 | |
CN1839884A (zh) | 鲜鹿茸冻干粉的制备及其含鲜鹿茸冻干粉的中药制剂和用途 | |
CN1879686A (zh) | 一种治疗禽病毒性疾病的中药组合物及制备方法 | |
CN1293898C (zh) | 治疗病毒性肝炎的药物组合物的制备方法 | |
CN1738633A (zh) | 来自药用植物的抗肥胖组分及其组合物 | |
CN1424057A (zh) | 一种中药免疫调节剂及其制法和在制药中的应用 | |
CN1316960C (zh) | 复方蛤青滴丸及其制备方法 | |
CN1679658A (zh) | 一种治疗艾兹病的中药制剂及其加工方法 | |
CN1251751C (zh) | 一种治疗慢性肝病及抗肝纤维化的中药及其制备工艺 | |
CN1634413A (zh) | 一种勒马回注射制剂及其制备方法 | |
CN1733055A (zh) | 胡芦巴提取物及其制备方法和应用 | |
CN1042395C (zh) | 蚁王精口服液及其制备方法 | |
CN1276764C (zh) | 一种中药组合物在制备治疗缺铁性贫血药物中的应用 | |
CN1541691A (zh) | 治疗急性黄疸肝炎的中药及其制备方法 | |
CN1927375A (zh) | 一种清热利湿,通淋消石的中药制剂及其制备 | |
CN1876112A (zh) | 一种治疗胃病的药物及其制备方法 | |
CN1814076A (zh) | 一种中药组合物的新用途 | |
CN1265805C (zh) | 降血糖中药口服制剂及其制备方法 | |
CN1557415A (zh) | 一种治疗肝胆疾病的药物制剂及其制备方法 | |
CN1263490C (zh) | 一种助阳药及其制备方法 | |
CN1283246C (zh) | 治疗急性胰腺炎的复方大黄素黄芩素注射液、冻干粉针及制备方法 | |
CN1281252C (zh) | 治疗泌尿系结石的药物组合物及其制备方法 | |
CN1181874C (zh) | 一种治疗急性脑出血的药物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Effective date of registration: 20070927 Pledge (preservation): Pledge |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20090205 Pledge (preservation): Pledge registration |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Effective date of registration: 20090205 Pledge (preservation): Pledge |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20121024 Granted publication date: 20050126 Pledgee: Agricultural Bank Chinese Longli County branch Pledgor: GUIZHOU RUIHE PHARMACEUTICAL Co.,Ltd. Registration number: 2009520000514 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Chinese medicine injection and its production process Effective date of registration: 20121024 Granted publication date: 20050126 Pledgee: Agricultural Bank Chinese Limited by Share Ltd. Longli County branch Pledgor: GUIZHOU RUIHE PHARMACEUTICAL Co.,Ltd. Registration number: 2012990000635 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20150925 Granted publication date: 20050126 Pledgee: Agricultural Bank Chinese Limited by Share Ltd. Longli County branch Pledgor: GUIZHOU RUIHE PHARMACEUTICAL Co.,Ltd. Registration number: 2012990000635 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Chinese medicine injection and its production process Effective date of registration: 20151008 Granted publication date: 20050126 Pledgee: Agricultural Bank Chinese Limited by Share Ltd. Longli County branch Pledgor: GUIZHOU RUIHE PHARMACEUTICAL Co.,Ltd. Registration number: 2015990000842 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
DD01 | Delivery of document by public notice |
Addressee: GUIZHOU RUIHE PHARMACEUTICAL Co.,Ltd. Document name: Notification to Pay the Fees |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Yang Xiangqian Document name: payment instructions |
|
DD01 | Delivery of document by public notice | ||
CX01 | Expiry of patent term |
Granted publication date: 20050126 |
|
CX01 | Expiry of patent term | ||
DD01 | Delivery of document by public notice |
Addressee: Yang Xiangqian Document name: Notice of Termination of Patent Rights |
|
DD01 | Delivery of document by public notice |